Inspirata to launch R&D facility in Bengaluru

To invest up to three million dollars to set up and operate the facility, will hire 50 product development engineers, scientists and informaticists with healthcare domain expertise

Inspirata, a cancer diagnostics solution provider with a digital pathology solution is launching its India operations with a research and development facility in Bengaluru. This facility is an extension of their US operations and will be set up and run at cost of around $3 million.

Inspirata intends to hire 50 software product development engineers, scientists and informaticists from the healthcare domain in the next two months. The Indian development centre aims to support all three of its business units, i.e. digital pathology work-flow solution, companion diagnostics and the cancer information data trust, and also will work on data mining, data analytics and predictive software algorithms.

Satish Sanan, CEO, Inspirata said, “The Indian R&D centre will play a very strategic and vital role in our endeavour to help speed up cancer diagnosis, research, teaching and most importantly provide doctors and patients with predictive data that will change the way cancer is diagnosed and treated. Bengaluru has the right ecosystem to support our plans and hence our decision to locate one of our key initiatives here.”

Inspirata has developed a digital pathology workflow solution that scans glass pathology slides, making the digital images available for high-resolution viewing and sharing anywhere in the world.

Reportedly, Inspirata’s pathology cockpit employs advanced computational image analytics algorithms called Companion Diagnostics that pre-screen and highlight suspicious cells on the digital images of glass pathology slides, helping pathologists to more rapidly diagnose cases.

These novel detection and diagnostic algorithms are expected to shorten the turnaround time for cancer detection and diagnosis from 12-13 days to two to three days. Additionally, patients will have more rapid and affordable access to second opinions and consultations from a worldwide pool of pathologists who specialise in specific forms of cancer.

The company also intends to develop a Cancer Information Data Trust—a database of cancer signatures cross-referenced to clinical treatment protocols and patient outcomes.

EH News Bureau